Skye Bioscience, Inc. (SKYE)
1.82
-0.02
(-1.09%)
USD |
NASDAQ |
Sep 03, 11:41
Skye Bioscience Cash from Operations (TTM) : -38.81M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -38.81M |
| March 31, 2026 | -42.44M |
| December 31, 2025 | -43.06M |
| September 30, 2025 | -41.47M |
| June 30, 2025 | -33.37M |
| March 31, 2025 | -29.71M |
| December 31, 2024 | -25.24M |
| September 30, 2024 | -20.91M |
| June 30, 2024 | -19.70M |
| March 31, 2024 | -14.60M |
| December 31, 2023 | -13.95M |
| September 30, 2023 | -14.98M |
| June 30, 2023 | -12.98M |
| March 31, 2023 | -13.89M |
| December 31, 2022 | -12.74M |
| September 30, 2022 | -9.841M |
| June 30, 2022 | -9.271M |
| March 31, 2022 | -8.042M |
| December 31, 2021 | -6.475M |
| September 30, 2021 | -6.292M |
| June 30, 2021 | -6.780M |
| March 31, 2021 | -6.136M |
| December 31, 2020 | -6.054M |
| September 30, 2020 | -5.771M |
| June 30, 2020 | -5.286M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.863M |
| December 31, 2019 | -6.028M |
| September 30, 2019 | -5.539M |
| June 30, 2019 | -4.867M |
| March 31, 2019 | -4.321M |
| December 31, 2018 | -3.943M |
| September 30, 2018 | -5.072M |
| June 30, 2018 | -4.356M |
| March 31, 2018 | -3.568M |
| December 31, 2017 | -3.331M |
| September 30, 2017 | -1.850M |
| June 30, 2017 | -2.262M |
| March 31, 2017 | -3.221M |
| December 31, 2016 | -3.553M |
| September 30, 2016 | -3.966M |
| June 30, 2016 | -4.750M |
| March 31, 2016 | -4.087M |
| December 31, 2015 | -3.690M |
| September 30, 2015 | -3.417M |
| June 30, 2015 | -3.074M |
| March 31, 2015 | -2.503M |
| December 31, 2014 | -1.755M |
| September 30, 2014 | -0.9605M |
| April 30, 2014 | -0.0014M |
| January 31, 2014 | -0.0059M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 4.681B |
| Viking Therapeutics, Inc. | -418.44M |
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Anika Therapeutics, Inc. | 5.977M |